Clinical Trial Update: CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for CF33-hNIS-antiPDL1 in metastatic triple-negative breast cancer shows the study is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CF33-hNIS-antiPDL1

Snippet

Sponsor: City of Hope Medical Center | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING